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Abstract
We have generated, via somatic cell nuclear transfer, two independent lines of transnuclear (TN)
mice, using as nuclear donors CD8 T cells, sorted by tetramer staining, that recognize the
endogenous melanoma antigen TRP1. These two lines of nominally identical specificity differ
greatly in their affinity for antigen (TRP1high or TRP1low) as inferred from tetramer dissociation
and peptide responsiveness. Ex vivo-activated CD8 T cells from either TRP1high or TRP1low mice
show cytolytic activity in 3D tissue culture and in vivo, and slow the progression of subcutaneous
B16 melanoma. Although naïve TRP1low CD8 T cells do not affect tumor growth, upon activation
these cells function indistinguishably from TRP1high cells in vivo, limiting tumor cell growth and
increasing mouse survival. The anti-tumor effect of both TRP1high and TRP1low CD8 T cells is
enhanced in RAG-deficient hosts. However, tumor outgrowth eventually occurs, likely due to T
cell exhaustion. The TRP1 TN mice are an excellent model for examining the functional attributes
of T cells conferred by TCR affinity, and they may serve as a platform for screening
immunomodulatory cancer therapies.
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Introduction
Infiltration of CD8 T cells correlates positively with patient outcomes, as shown for
colorectal and other cancers (1, 2). Even in the absence of a successful endogenous anti-
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tumor immune response, immunotherapy for cancer has begun to deliver on its promise (3,
4). The success of checkpoint blockade therapies such as anti-CTLA-4 illustrates the
importance of the CD8 T cell response in tumor regression. At baseline, many human cancer
patients have anti-tumor CD8 T cells that are anergic or kept in check by regulatory CD4 T
cells (Tregs). CTLA-4 blockade can activate anti-tumor T cells and elicit clinical responses
in 25% of patients. Anti-CTLA-4 works synergistically with chemotherapy, radiation, or
other therapies that generate tumor lysis and uptake of tumor antigens by dendritic cells (5).
Blocking antibodies to PD-1 and PDL1 (6, 7) produce similar outcomes. The endogenous T
cell response to tumors correlates with overall survival in cancer patients (1), and therapies
aimed at boosting the T cell response are now in widespread use (3, 8).
Many tumor antigens are mutated self antigens or antigens that are over-expressed. TCRs on
T cells that recognize such antigens are generally of low affinity (9) since high-affinity self-
reactive cells are deleted in the thymus (10, 11) and suppressed in the tumor
microenvironment (12). The type of CD8 T cell response necessary for optimal tumor
rejection remains poorly characterized due to a paucity of animal models. Most of the
available animal models make use of TCR transgenic animals, the construction of which is
based on long term T cell cultures from which the corresponding rearranged TCR segments
are cloned and expressed as transgenes. Alternatively, tumor cell lines are engineered to
express antigens for which TCR transgenics happen to be available. By their very nature,
populations of T cells harvested from tumor-bearing animals or tumor-infiltrating
lymphocytes are necessarily heterogeneous, polyclonal and variable from one experiment to
the next, exactly the reason why TCR transgenics are so widely used. Models of anti-tumor
immunity typically rely on overexpression of ovalbumin in combination with OTI transgenic
T cells, known to be of very high affinity. Pmel TCR transgenic mice contain CD8 T cells of
more moderate affinity for the endogenous melanoma antigen tyrosinase related protein 1
(TRP1), but results from these mice are difficult to compare to ovalbumin/OTI systems due
to differences in the antigen.
Somatic cell nuclear transfer may be used to clone mice from the nuclei of antigen-specific
lymphocytes (13–16). These transnuclear mice are derived from primary CD8 T cells
harvested in the course of a natural immune response, without any prolonged tissue culture
to select for high affinity T cell variants in vitro. TN mice contain no genetic alterations
other than the rearranged TCR genes, expressed from their endogenous loci and under
physiological control. Finally, creation of TN mice can be done rapidly, requiring only 6
weeks from isolation of a selected lymphocyte population, accomplished through isolation
of Class I MHC-tetramer positive cells, to birth of chimeric mice. A key advantage of the
transnuclear technology is the ability to clone multiple lines of mice with the same antigenic
specificity but with different TCR sequences and therefore different affinities (15). These
mice can then be used as a ready source of lymphocytes of defined specificity for in vitro
culture or for adoptive transfer experiments.
Most tumors are weakly immunogenic at best. The well-studied melanoma cell line B16
downregulates Class I MHC and is poorly infiltrated by immune cells (17–19). CD8+ T cells
can reject B16 in vivo, but only when mice are first exposed to some form of immune
manipulation, such as vaccination with irradiated B16, engineered to secrete the cytokine
GM-CSF (18, 20, 21). Since B16 does not induce a detectable CD8+ T cell response under
normal conditions, we used a peptide-based vaccine strategy to elicit a robust CD8+ T cell
response to the melanoma-specific antigen tyrosinase-related protein 1 (TRP-1). This
vaccine consists of a palmitoylated version of the peptide to increase its circulatory half-life,
anti-CD40 antibody, and the TLR3 ligand polyinosine-polycytidylic acid (poly-IC) and is
referred to as TRIVAX. When administered to mice, it elicits a robust population of tetramer
+ CD8+ T cells that can reject established B16 tumors (22, 23).
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We have used such vaccine-induced CD8 T cells as a source of donor nuclei to generate two
independent lines of TRP1-specific transnuclear mice. In so doing, we have generated, for
the first time, a pair of transnuclear mice with TCRs specific for the identical peptide-MHC
combination. These TCRs are expressed under the control of their endogenous promoters
and represent cells directly harvested from an immunized mouse upon staining with the
appropriate Class I MHC tetramers, without pre-selection in tissue culture, and differ in their
affinity for TRP1 by approximately 100-fold. The T cells from these mice recognize an
endogenous tumor antigen and allow a direct assessment of the role of TCR affinity in anti-
tumor CD8 T cell responses. The generation of anti-tumor TN mice provides a unique set of
tools for the fields of tumor immunology and CD8 T cell development.
Materials and Methods
Animal care
All animals were housed at the Whitehead Institute for Biomedical Research and were
maintained according to protocols approved by the MIT Committee on Animal Care. C57Bl/
6, CD45.1 congenics, and OT-I transgenic mice were purchased from Jackson Labs.
RAG2−/− (RAG2TN12) mice were purchased from Taconic.
TN mouse generation
TN mice were generated as previously described (14,15, 24). Briefly, CD8+ TRP1 tetramer+
cells were sorted by FACS and used as a source of donor nuclei for SCNT. The mitotic
spindle was removed from mouse oocytes and replaced with donor nuclei. The nucleus-
transplanted oocytes were then activated in medium containing strontium and TSA, and
allowed to develop in culture to the blastocyst stage. Because the live birth rate of SCNT
blastocysts is close to zero, SCNT blastocysts were instead used to derive embryonic stem
(ES) cell lines. These ES cell lines were then injected into wild type B6xDBA F1 blastocysts
and implanted into pseudopregnant females. The resulting chimeric pups were mated to
C57Bl/6 females to establish the 6.15 (TRP1low) and 6.17 (TRP1high) lines. All animals used
were backcrossed 4–7 generations onto the C57BL/6 background.
Sequencing of the TCR genes
TRP1high and TRP1low CD8 T cells were purified by positive selection using CD8 magnetic
beads (Miltenyi Biotec) and used as a source of RNA. 5′RACE was performed according to
the manufacturer’s protocol (GeneRacer, #L1502-01 Invitrogen).
MHC tetramer production and peptide exchange
Recombinant protein expression, refolding of the H-2Db complex with the SV9-P7*
conditional ligand, and their subsequent tetramerization were accomplished by following
established protocols (25–27). The peptide exchange reaction was initiated by UV
irradiation (360 nm), and the resulting MHC tetramers were used directly to stain freshly
prepared splenocytes as described previously. TRP1 altered peptide ligands were produced
by Fmoc-based solid-phase peptide synthesis by the MIT Center for Cancer Research
(Cambridge, MA) biopolymers facility. All peptides were dissolved in dimethyl sulfoxide
(10 mg/ml) and stored at −20°C until further use.
Flow cytometry
Cells were harvested from spleen, peripheral blood or thymus. Cell preparations were
subjected to hypotonic lysis to remove erythrocytes, stained and analyzed using a
FACSCalibur (BD). Tetramers were prepared fresh from photocleavable stocks (25–27) or
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directly refolded with TRP1 heteroclytic peptide (TAPDNLGYM). All antibodies were from
BD Pharmingen.
Cell culturing
Cells were cultured in RPMI 1640 medium supplemented with 10% heat-inactivated FBS, 2
mM l-glutamine, 100 U/ml penicillin G sodium, 100 μg/ml streptomycin sulfate, 1 mM
sodium pyruvate, 0.1 mM nonessential amino acids, and 0.1 mM 2-ME. Bone marrow-
derived dendritic cells were obtained by culturing of bone marrow aspirates in RPMI media
supplemented with rmGM-CSF (Peprotech) and rmIL-4 (Peprotech). Fresh media was added
to the BMDC cultures every 2 days for 6 days. BMDCs were used at day 6–8 of
differentiation, and were washed prior to use. CD8 T cells were isolated from pooled spleen
and LNs of TRP1 TN or wild type mice using positive selection on anti-CD8 magnetic
beads (Dynabeads, Invitrogen). For cocultures, BMDCs were pulsed with the indicated
peptides for 30 minutes prior to the addition of CD8 T cells at a ratio of 100,000 T cells to
50,000 BMDCs in round-bottom 96 well culture plates. IL-2 and IFN-γ production were
measured by ELISA of 24, 48 or 72 hour culture supernatants as indicated (BD
Pharmingen). RANTES and MIP-1β were measured by cytokine bead array (BD).
3D B16 tumor cultures
CD8 T cells from TRP1high, TRP1low or OT-I transgenic mice were isolated by positive
selection on anti-CD8 Dynabeads(Invitrogen, 114.62D) and cultured for 18 hours with
BMDCs plus either TRP1 heteroclytic peptide or OVA peptide (SIINFEKL) at 1μM
concentration. Activated CD8 cells were then counted mixed with B16 cells at 20:1 ratio and
resuspended in 3-D culture matrix cocktail as follows: D-PBS containing 33% of Cultrex
BME (Trevigen 3445-005-01), 10% FCS, 1 mg/ml Fibrinogen (Calbiochem, 341578), 1.4
U/mL Thrombin (MP Biomedicals, 02194083), 1.25×105 cells/mL of B16 and 2.5×106 or
5.0×106 cells/mL of CD8+ T-cells. 55μl of this cell+matrix cocktail was cast in flat bottom
96 well plates, incubated for 45 minutes to allow the matrix become solid and then overlaid
with 100 μl of DMEM+10% FCS medium on top of the solid gel matrix. Cultures were
incubated for 4 days. Cells were reisolated in ice-cold PBS+5mM EDTA, washed, and
resuspended in PBS+0.5% BSA and stained using anti-CD8 and the viability dye 7-AAD
(BD Pharmingen). B16 cells were quantified as a ratio of 7-AAD+ to 7-AAD− cells to
determine the dead:live ratio.
B16 tumor inoculations
B16 cells were a kind gift of Dr. Glenn Dranoff (Dana Farber Cancer Institute, Boston,
MA). B16 cells were cultured to 90% confluency, trypsinized, washed in HBSS and
resuspended in HBSS at 50,000 tumor cells per 250uL volume. Cells were injected
subcutaneously in the left flank of 6–12 week old female C57BL/6 mice. In mice receiving
no transferred T cells, palpable tumors arose 7–10 days post-inoculation. Tumor diameter
was measured in 3 dimensions, and mice were sacrificed when tumor volume reached 2
cubic cm. For adoptive transfers, unless otherwise stated, mice received 300,000 CD8 T
cells in 150μL PBS administered via tail vein injection within 24 hours of tumor inoculation.
Statistics
Statistical analysis of survival curves was performed using GraphPad Prism software. p
values were determined using the Mantel-Cox log rank test. Delays in tumor growth were
obtained by comparison of median survival times.
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Results
Generation of high and low affinity TRP1 TN mice
Vaccination with palmitoylated TRP-1 peptide, anti-CD40 antibody, and the TLR3 ligand
polyinosine-polycytidylic acid (poly-IC) yields a robust population of anti-TRP-1 CD8+ T
cells relatively quickly and provides a source of TRP-1 specific lymphocytes for SCNT.
SCNT is most successful using hybrid mouse strains as a source of donor nuclei. To this
end, B6x129 F1 male agouti mice were injected intravenously with palmitoylated peptide
TAPDNLGYM, anti-CD40 and poly-IC. The TRP1 peptide sequence used differs from
native TRP1 in the 9th position (A to M substitution) to increase its binding to H-2Db. This
heteroclitic peptide was used to construct TRP1 tetramers, and robust TRP-1 tetramer
positive populations were observed in the spleens of immunized mice at 6 and 8 days post-
immunization (Figure 1A). These CD8+ TRP-1 tetramer+ populations were sorted by FACS
and used as a source of donor nuclei for two separate SCNT experiments. A total of 105
nuclear transfers were performed, yielding 5 independent ES cell lines (Figure 1B). Of
these, two resulted in agouti chimeric mice containing TRP-1 tetramer+ CD8+ T cells in
peripheral blood (Figure 1C).
Both lines of TRP1 transnuclear mice gave germline transmission, and the F1 progeny
showed skewing of the CD4:CD8 ratio, with a large percentage of TRP1 tetramer+ cells at
baseline (Fig 1D). Tetramer+ CD8 T cells were sorted from each mouse line and subjected
to 5′RACE to sequence the TCRα and TCRβ genes (Supplemental Figure 1). The 6.15 mice
had consistently fewer TRP1 tetramer+ cells than their 6.17 counterparts, and the tetramer
staining was dimmer, as judged by a reduction in mean fluorescent intensity. TCR, CD3 and
CD8 surface expression were normal on 6.15 cells (data not shown), so we hypothesized
that the lower intensity tetramer staining was due to weaker binding of tetramers to the TCR.
To measure TCR avidity, splenocytes from 6.15 or 6.17 mice were incubated with TRP1
tetramer at saturating conditions, washed, and incubated for various periods of time to allow
dissociation of the TCR-peptide-MHC complexes (Figures 2A and 2B). 6.15 cells rapidly
lost tetramer staining, such that by 30 minutes all cells were tetramer-negative and
indistinguishable from background. 6.17 cells lost fluorescence over time, but a significant
fraction remained tetramer-positive even after overnight incubation. Thus, CD8 T cells from
6.17 mice show slower tetramer dissociation than do 6.15 cells (t1/2 = 41 min vs. 4.9 min);
we therefore reclassified these TN mouse lines as TRP1high and TRP1low, respectively.
The degree to which cultured CD8 T cells can produce cytokines in response to properly
presented serial dilutions of peptide correlates with anti-tumor function (28). We cultured
isolated CD8 T cells from TRP1 TN mice with bone marrow-derived DCs (BMDCs) pulsed
with different amounts of TRP1 peptide, either the heteroclitic variant used for tetramer
staining or the native TRP1 sequence. TRP1low T cells were unable to respond to the
heteroclitic TRP1 peptide at concentrations less than 100 pg/mL while TRP1high T cells
secreted IFN-γ in response to as little as 1 pg/mL peptide under the same conditions (Figure
2C). Both TRP1high and TRP1low cells produced IFN-γ in response to native TRP1 peptide,
but higher concentrations of peptide were required (Figure 2D). In addition to IFN-γ, we
also measured chemokine production. TRP1low cells produced RANTES and MIP1-α even
when exposed to concentrations of peptide (Figure 2E) that yielded negligible IL-2 or IFN-γ
production, confirming previous studies showing a hierarchy of effector functions based on
TCR affinity (29).
TRP altered peptide ligands assess fine specificity of TCR
A panel of TRP1 altered peptide variants was generated (Figure 3A) that differed from the
heteroclitic reference peptide by single amino acid substitutions. No substitutions were made
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in anchor residue positions. Sorted CD8 cells from TRP1high and TRP1low mice were
incubated with BMDCs pulsed with the altered peptide ligands to assess IL-2 and IFN-γ
production (Figure 3B). TRP1high T cells were more promiscuous than TRP1low T cells.
One peptide (A1) generated similar levels of both IL-2 and IFN-γ from both TRP1high and
TRP1low CD8 cells, demonstrating that the lower cytokine production typically observed
from cells from TRP1low mice is not an intrinsic limit on the ability of these cells to produce
cytokine.
Minor differences between TRP1high and TRP1low cells during thymic development and in
the naïve state
We compared the surface profile of naïve CD8 cells from age-matched TRP1 TN mice and
found that TRP1low cells show higher expression of NK1.1 and KLRG1 than TRP1high or
wild type control cells (Figure 4A). No differences were seen in Tim3 or CD25 staining,
suggesting that NK receptor upregulation is not a function of global activation state, but
rather an intrinsic difference established by the clonotypic T cell receptors.
CD5 expression correlates with intensity of TCR signaling and is tightly regulated during T
cell development (30). TRP1low cells also expressed lower levels of CD5 in both the
periphery and during thymic development, while TRP1high cells showed a curious peak of
CD5 expression in CD4+CD8+ thymocytes (Figure 4B). TRP1high cells show a decrease in
CD4+CD8+ thymocytes and an increase in TCRβ and CD3ε expression at the CD4+CD8+
stage, indicative of accelerated thymic development, as is typical of mice with pre-
rearranged TCR genes. TRP1low cells did not show accelerated thymic development.
Overall, thymic development in both TRP1 TN mouse strains is near-normal, and the T cells
produced have a naïve phenotype.
TRP1 TN CD8 T cells are cytotoxic in vitro
To determine whether TRP1 cells could be cytotoxic, we activated TRP1high and TRP1low
CD8 T cells with anti-CD3/CD28 coated beads for 7 days and cultured with TRP1 A1
peptide-pulsed GFP+ B cells mixed with unlabeled B cells at a 1:1 ratio. Both high and low
affinity TRP1 cells displayed specific killing in a dose-dependent fashion, with TRP1low
cells slightly outperforming TRP1high cells (Figure 5A). To determine whether TRP1 TN
cells could exert cytotoxic function against tumor cells, we established 3D cocultures using
B16 cells and CD8 T cells seeded together in Matrigel. B16, whether grown in culture or
explanted from a mouse, expresses TRP1 protein as evidenced by immunoblotting (Figure
5B). Coculture of B16 and TRP1 TN cells showed an increase in the ratio of dead/live tumor
cells in groups that received either TRP1low or TRP1high CD8 T cells. These results show
that both lines of TRP1 TN cells can be cytotoxic under 3D culture conditions (Figure 5C).
Again, TRP1low cells tended to show greater cytotoxicity than TRP1high cells although these
differences did not reach statistical significance.
TRP1 TN cells delay tumor growth in vivo
To assess their tumor-protective function in vivo, naive CD8 T cells isolated from TRP1high
or TRP1low mice were transferred into wild type recipients simultaneously with
subcutaneous inoculation with B16 melanoma. The B16 dose of 50,000 cells was
empirically determined such that tumors would first become palpable at day 7–10 post-
inoculation and 50% of untreated mice would require euthanasia by 21 days post-
inoculation. Under these conditions, administration of naïve TRP1high cells showed a
modest 2 day difference in median survival while TRP1low cells had no discernible effect on
tumor growth (Figure 6A). Administration of multiple doses of naïve CD8 T cells (at days 0,
3, and 5 post tumor inoculation) gave similar results to single dose trials, with TRP1high
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cells conferring a 2 day survival benefit and TRP1low cells having no discernible effect (data
not shown).
We next analyzed the effect of ex vivo activation of the TRP1 cells prior to adoptive transfer.
CD8 T cells from TRP1high or TRP1low mice were cultured with BMDCs and TRP1 peptide
for 18 hours and transferred into wild type hosts at day 1 post-inoculation with B16. Under
these conditions, both TRP1high and TRP1low cells conferred a 4 day increase in mean
survival (Figure 6B). Thus TRP1low cells acquire anti-tumor properties equal to their high
affinity counterparts upon ex vivo activation. As further confirmation, CD8 T cells from the
same TRP1low donor mouse were adoptively transferred either naïve, or after culture with
peptide-pulsed BMDCs (Figure 6C). Although activation of polyclonal CD8 T cells has a
modest effect, possibly due to the selective expansion of TRP1-specific cells from the
polyclonal pool, activated TRP1low cells conferred an additional 5 day increase in median
survival when compared to polyclonal activated CD8 T cells (Figure 6C).
Studies using transgenic CD8 T cells from Pmel mice have shown that decreasing the
number of transferred CD8 T cells leads to increased proliferation rates and increased anti-
tumor effects of the transferred cells (31). In Figures 6A–C, we administered a constant dose
of 3 million TRP1 cells per mouse. Peptide-activated TRP1high cells retained their anti-
tumor activity at lower doses, and showed optimal anti-tumor effect at a dose of 300,000–
500,000 cells (Figure 6D); the 300,000 T cell dose was used for all subsequent experiments.
To assess possible synergy between TRP1high and TRP1low cells, purified CD8 T cells from
each TN mouse line were peptide-activated ex vivo and transferred into wild type hosts,
either alone or mixed at a 1:1 ratio. The total number of transferred T cells remained
constant. The combination of TRP1high plus TRP1low cells did not confer additional survival
benefit beyond what could be seen with either population alone (Figure 6E).
The cumulative effect of activated TRP1 TN cells against subcutaneous B16 caused a delay,
but did not prevent tumor growth. This eventual failure to control the tumor could be due to
several factors: 1) incomplete activation of the TRP1 TN cells ex vivo; 2) failure to traffic to
the tumor; 3) immunosuppression in the tumor microenvironment; or 4) loss of the TRP1
epitope. To address some of these issues, we first cultured TRP1high cells with anti-CD3/
CD28 coated beads and found that 40% of mice survived (Figure 6F). We next transferred
naïve TRP1high or TRP1low cells into RAG-deficient mice to induce homeostatic
proliferation of the transferred T cells and to observe TRP1 TN CD8 T cell function in the
absence of CD4+ Tregs. When challenged with B16, the RAG-deficient mice reconstituted
with either TRP1high or TRP1low cells showed a 7 day delay in tumor growth (Figure 7A).
The tumors harvested from RAG-deficient mice in Figure 7 were melanotic, showing that
melanin production was intact. Immunoblotting for TRP1 protein showed no decrease in
overall TRP1 levels (data not shown). A more likely explanation for the eventual failure of
CD8 T cells to control tumor growth is exhaustion. In RAG-deficient hosts, which lack
endogenous T cells, the tumor infiltrating CD8 T cells are derived entirely from the
transferred TRP1 TN population. Both TRP1high and TRP1low cells can migrate to the
tumor, yet even when they accumulate to the extent seen in RAG-deficient hosts, they
eventually fail to control tumor outgrowth. Surface expression of PD-1 and LAG3 was
increased on TRP1 TN cells harvested from end-stage tumors (Figure 7B), consistent with
exhaustion (32, 33).
Discussion
The role of TCR affinity in the anti-tumor T cell response remains a topic of debate. On the
one hand, the endogenous pool of anti-tumor T cells is generally low affinity, presumably
because T cells bearing high affinity TCRs that might recognize antigens on tumors are
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deleted in the course of thymic development, as most such antigens represent self-antigens
expressed at supranormal levels. Tumor-specific CD8 T cells express TCRs of much lower
affinity than typical anti-viral T cells, as was recently quantified for 24 different human
TCRs (9). The repertoire of anti-tumor TCRs is limited not only by thymic deletion of high-
affinity self-reactive clones but also by negative regulatory mechanisms in the tumor
environment. However, high affinity anti-tumor T cells can be generated in experimental
mouse models or can be expanded by ex vivo culturing of human samples. The increased use
of chimeric antigen receptors (34, 35), usually selected to display higher affinities for their
cognate antigens than those of typical endogenous TCRs, demands a better understanding of
these supraphysiologic binding affinities: how does increased TCR affinity affect functional
outcomes such as cytokine production, cytotoxicity and memory formation? The role of
TCR affinity with respect to tumor destruction and long-term anti-tumor memory is
therefore an important question and at a minimum would require the comparison of T cells
that recognize the same antigen with different affinities.
Although intuitively the highest affinity T cells would seem to be the most efficacious at
tumor regression, the situation is likely more complicated. In human CMV infection, a
population of T cells with such low affinity that they fail to bind MHC tetramers still
produces more IFNγ and is more cytotoxic than higher affinity T cells from that same
individual (36). Several lines of evidence suggest that a CD8 T cell’s fate is determined, or
programmed, by its initial encounter with antigen (37–39). Duration and strength of
antigenic stimulation are inversely correlated with CD8 memory cell differentiation during
acute viral infection (38, 39). Low affinity T cells can increase their functional avidity by
upregulating expression of CD8. Conversely, high affinity T cells downregulate CD8
expression in order to avoid antigen-induced cell death (39, 40). Upon encountering
abundant antigen, high avidity CD8 T cells cease proliferation and initiate apoptosis,
although they can still exert cytotoxic function prior to death (18).
Adoptive cell transfer therapy, as pioneered by the Rosenberg group, selects for the highest
affinity CD8 T cells and aims for maximal activation in vitro prior to infusion into the
patient. This strategy has been remarkably successful in a limited clinical population (41–
43), and suggests that high affinity, maximally activated CD8 T cells confer the maximal
anti-tumor response. Likewise, comparison of two different T cell lines specific for the same
model antigen overexpressed in the pancreas showed that the higher affinity Clone 4 cells
were better able to expand in the pancreatic environment and cause tumor destruction, as
measured by increased serum glucose (44) although low affinity Clone 1 cells were able to
mediate tumor destruction when paired with antigen-specific CD4 cells (45). However,
when the same Clone 4 cells were injected into mice with HA-expressing renal cell
carcinomas, the anti-tumor effects of high affinity Clone 4 cells were curtailed by
suppressive mechanisms in the tumor microenvironment (46). Sequence analysis of TCRs
from T cells induced by effective versus ineffective vaccine strategies shows that higher
affinity T cells were induced by the effective vaccines, although the KD values measured for
each group differed by less than 2-fold (47).
On the other hand, several studies have suggested that an optimal CD8 T cell response uses
low to moderate affinity TCRs. Retroviral transduction of T cells with a panel of TCRs of
known gradations in affinity showed that the highest affinity TCRs were absent from tumor-
infiltrating CD8 T cells, although these TCRs could be found on tumor-infiltrating CD4
cells (48). A panel of NY-ESO1 specific T cell lines engineered to express TCRs with
affinities ranging from low to supra-physiological showed that optimal cytotoxicity and
calcium flux occurred using TCRs with intermediate KD values of 1–5 micromolar with a
decline in functionality for higher affinity TCRs (49, 50). A similar ceiling was observed
using vaccination with peptide mimetics with a range of affinities for a given T cell clone
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(51). A recent study evaluated a large panel of human anti-melanoma cell lines for peptide
sensitivity, production of various cytokines and TCR affinity as defined by the kinetics of
multimer binding. Although peptide sensitivity and production of IL-2, TNFα and IFN-γ
correlated with tumor cell killing, multimer binding failed to correlate with any of the
functional parameters measured (28), suggesting that TCR affinity alone could not predict
anti-tumor responses. This raises the interesting possibility that attributes other than affinity,
yet associated with a particular TCR clonotype, may determine the functional property of a
T cell. Using tumors transduced with altered peptide ligands for OT-I CD8 T cell
recognition, low affinity TCR interactions generated enhanced cytokine production during
both primary and secondary responses, but the lower affinity T cells were more susceptible
to TGF-β mediated suppression (52). An interesting study compared the TCR affinity of the
endogenous CD8 response to ovalbumin-expressing glioma as a function of the vaccine
injection site (53). Mice vaccinated at sites proximal to the tumor generated lower affinity
CD8 T cells than mice vaccinated at more distant sites, which could implicate suppressive
mechanisms that specifically limit high-affinity CD8 priming in the tumor draining lymph
nodes (53).
In the TRP1 TN system, we show that an approximately 10-fold difference in tetramer
dissociation rates and a 100-fold difference in peptide responsiveness have almost no effect
on the overall anti-tumor function of the transferred CD8 T cells. How do the low affinity T
cells manage to perform as well as their high affinity counterparts? Although tetramer
dissociation and IFN-γ production showed clear distinctions between the two TRP1-specific
TN lines, we observed much less of a difference when comparing cytotoxic function in a 3D
culture model. Likewise, both TRP1high and TRP1low cells produced the chemokines
RANTES and MIP1α when stimulated with picomolar concentrations of native TRP1
peptide, conditions under which no IL-2 or IFN-γ could be detected in supernatants from the
TRP1low cultures. Since the concentration of antigen presented in a tumor-bearing mouse is
likely to be small, the fact that TRP1low cells produce monocyte-attracting chemokines in
response to low doses of peptide could be relevant for how TRP1low CD8 T cells influence
the tumor microenvironment. Likewise, the increased IL-2 production from TRP1high cells
could enhance Treg recruitment or proliferation in the tumor microenvironment, although
such an effect would be eliminated in RAG-deficient hosts, which lack Tregs. Another likely
possibility is increased activation-induced cell death of TRP1high cells in the tumor
environment, which could limit the efficacy of high affinity CD8 cells (54, 55). Indeed,
TRP1high tumor infiltrating cells show reduced CD8 expression, indicative of a more
activated state.
Here we have generated a pair of mice with T cells specific for the same MHC-peptide
combination but differing in affinity by one to two orders of magnitude. The TCR α and β
chains are under the control of their endogenous promoters, and expressed at physiological
levels. Both TCRs were selected by directly harvesting tetramer+ CD8 cells from a
vaccinated mouse without any selection in tissue culture, and thus are representative of the
normal pool of activated CD8 T cells that arises during an immune response. As such, we
anticipate that the TRP1 TN mice reported here may be useful for studies of T cell
development and T cell activation.
Although TRP1 is a self-antigen expressed in healthy melanocytes, we did not observe
vitiligo in TRP1high or TRP1low mice on a RAG-proficient background, suggesting a
possible role for CD4+ regulatory T cells. Tregs are absent in TRP1high RAG2−/− mice, and
these mice develop a mild spontaneous vitiligo around 3 months of age, affecting primarily
the periorbital region. The Tregs that develop in TRP1 TN mice are constrained to using a
single TCR Vβ8.2 or TCR Vβ5 respectively, thus limiting the diversity of potential Tregs
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specificities in these mice. Nevertheless, the Tregs that develop are apparently adequate to
prevent autoimmunity even in the presence of a high fraction of autoreactive CD8 T cells.
TRP1 can serve as a tumor rejection antigen, and we show a modest anti-tumor effect of
anti-TRP1 CD8 T cells as a monotherapy. Although the effects are small, the delay in tumor
growth and slight increase in overall survival parallels the human situation, where
monotherapies such as anti-CTLA-4 also show modest clinical benefit (56). A future
challenge for tumor immunology will be to determine which therapies synergize in order to
achieve maximum clinical effect. CD8 T cell exhaustion is commonly observed in human
patients, and must be overcome in order for immunotherapy to succeed. The TRP1 mice
offer an excellent pre-clinical platform for testing the immune modulatory effects of
potential new drugs or drug combinations.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1.
TRP1 TN mice were derived from TRP1-specific CD8 T cells. A) C57BL/6x129 F1 agouti
male mice were immunized with TRIVAX (palmitoylated TAPDNLGYM 10μg/mouse,
anti-CD40 30μg/mouse and poly-IC 15 μg/mouse) intravenously. Splenocytes were
harvested 6 or 8 days post-immunization and stained with anti-CD8 and TRP1 tetramer.
Gated cells were sorted by FACS and used as nucleus donors for SCNT. B) Success rate of
nuclear transfer. C) ES cell lines 6.15 and 6.17 were injected into wild type blastocysts to
generate chimeric mice as shown. Germline transmission was achieved by crossing chimeras
to C57BL/6 females. D) Peripheral blood mononuclear cells were harvested from germline
transmitted 6.15 or 6.17 mice and stained with TRP1 tetramer, anti-CD4 and anti-CD8. The
calculated CD4:CD8 ratio is shown below each plot. Note the lower intensity tetramer
staining in the 6.15 mouse, representative of more than 100 mice analyzed.
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Figure 2.
TRP1 TN lines differ in TCR affinity. A) Splenocytes from TRP1low (6.15) and TRP1high
(6.17) TN mice were stained with TRP1 tetramer to saturation, washed, and incubated at
room temperature for various times prior to fixation and analysis by flow cytometry. Time 0
is shown. B) Percent tetramer+ cells as defined by the gates shown in A were calculated for
each time point and normalized to Time 0. Representative of 3 independent experiments. C)
CD8 T cells isolated from TRP1low or TRP1high mice were cocultured with BMDCs pulsed
with TAPDNLGYM at the indicated concentrations. IFN-γ was measured by ELISA of 48
hr culture supernatants. Representative of 5 independent experiments. D) CD8 T cells were
cocultured as in (C) using BMDCs pulsed with the native TRP1 peptide (TAPDNLGYA).
Representative of 3 independent experiments. E) CD8 T cells were cultured as in (C).
RANTES and MIP-1α were analyzed by cytokine bead array using 24 hr culture
supernatants; IL-2 was measured by ELISA of the same supernatants. Representative of 3
independent experiments.
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Figure 3.
Fine specificity mapping of TRP TN TCR specificities. A) An altered peptide library (as
shown) was generated by substitution of non MHC contact residues. B) CD8 T cells isolated
from TRP1high or TRP1low mice were cocultured with BMDCs pulsed with the indicated
peptides at 100 ng/mL. IL-2 was measured by ELISA of 24hr culture supernatants. IFN-γ
was measured by ELISA of 72hr culture supernatants. Representative of 2 independent
experiments. Error bars are SD of triplicate samples.
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Figure 4.
Surface profiling and thymic development of TRP1 TN CD8 cells. A) Pooled spleen and
lymph node cells from 6 week old male TRP1high, TRP1low and C57BL/6 mice were stained
with the indicated antibodies. Plots shown are gated on CD8+ cells. B) Thymocytes from 6
week old male TRP1high, TRP1low and C57BL/6 mice were stained with the indicated
antibodies. Histogram plots are gated on CD4+CD8+ double positive cells (top rows) or on
CD8+ single positive cells (bottom rows). Numbers indicate median fluorescent intensities
of histograms. TRP1low cells show negligible tetramer staining. To confirm genotype, naïve
CD8 T cells from the same mice were stimulated with APCs and TRP1 A1 peptide in tissue
culture, and activation was assessed by CD69 expression. %CD69+: TRP1high = 81% (no
peptide =0.5%); TRP1low = 35% (no peptide = 0.3%).
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Figure 5.
TRP1 TN CD8 T cells are tumoricidal in vitro. A) CD8+ T cells were harvested from the
indicated mice and cultured for 8 days with anti-CD3/CD28 beads and IL-2 (20 U/mL).
Activated T cells were washed, counted, and aliquoted into a 96 well round bottom plate at
50,000 T cells per well. B cells were harvested from a wildtype or MHCII-GFP mouse. GFP
+ B cells were incubated with 100uM TRP1 A1 peptide for 2 hours, washed twice, counted
and mixed with non-GFP cells at a 1:1 ratio. This B cell mixture was then added to the
plated T cells at the indicated ratios where E = effector T cells and T = total pooled B cells.
After 48 hours of coculture, the cells were stained with anti-CD19 and the viability dye 7-
AAD. B) Lysates were prepared from cultured B16 or Panc02 cells, and from B16 tumors
>1cm in diameter resected from tumor-bearing mice. Immunoblotting shows TRP1 protein
expression. C) CD8 T cells were cultured for 18 hours with BMDCs and their cognate
peptide to induce activated. Peptide activated CD8 T cells were counted, washed, and
seeded with B16 cells in Matrigel at 10:1 ratio. 3D cultures were incubated for 4 days; cells
were reisolated and stained with anti-CD8 and the viability dye 7-AAD. B16 cells were
gated by FSC/SSC profile of CD8− cells. The ratio of 7AAD+:7AAD− cells is shown.
Representative of 2 independent experiments. Error bars are SD. * p=0.026, ** p=0.005 vs.
OT-I.
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Figure 6.
TRP1 CD8 T cells delay tumor growth in vivo. A) Naïve CD8 T cells were harvested from
TRP1high, TRP1low or wild type mice and transferred at 3 million cells per mouse into
female C57BL/6 recipients. On the same day, 50,000 B16 tumor cells were inoculated
subcutaneously. Tumor volume was measured over time, and mice were euthanized when
tumor size reached 2 cm3. n=30 mice per group, pooled from 3 independent experiments.
**p=0.0001 vs. polyclonal CD8. B) CD8 T cells were harvested from TRP1 TN mice and
cultured with BMDCs pulsed with TRP1 heteroclytic peptide for 18 hours. CD8 cells were
harvested, washed, counted and transferred to recipient C57BL/6 mice at 3 million cells per
mouse one day after inoculation with 50,000 B16 cells. n=30 mice per group, pooled from 3
independent experiments. *p=0.0119, **p=0.0161 vs. polyclonal CD8. C) CD8 T cells were
harvested from TRP1low or C57BL/6 donor mice and transferred into recipients either
directly (naïve) or after 18 hours of culture with peptide-pulsed BMDCs (activated).
Recipient mice were inoculated with B16 cells on the same day as naïve cell transfer, or one
day prior to activated cell transfer. **p=0.001 vs polyclonal CD8 naïve, ***p=0.0005 vs,
polyclonal CD8 activated. D) CD8 T cells were harvested from TRP1 TN mice and cultured
with BMDCs pulsed with TRP1 heteroclytic peptide for 18 hours. CD8 cells were harvested,
washed, counted and transferred to recipient C57BL/6 mice at the indicated number of cells
per mouse one day after inoculation with 50,000 B16 cells. n=10 mice per group.
*p=0.0361, **p=0.012, ***p=.0045, ****p=0.0011, *****p<0.0001 vs. polyclonal CD8. E)
CD8 T cells were harvested from TRP1 TN mice and cultured with BMDCs pulsed with
TRP1 heteroclytic peptide for 18 hours. CD8 cells were harvested, washed, counted and
transferred to recipient C57BL/6 mice at 300,000 cells per mouse one day after inoculation
with 50,000 B16 cells. n=10 mice per group. *p=0.0047, **p=0.0008, *** p=0.0004 vs.
polyclonal CD8. F) CD8 T cells were harvested from C57BL/6 mice or TRP1high mice and
cultured for 5 days with anti-CD3/CD28 coated beads. CD8 cells were harvested, washed,
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counted and transferred into C57BL/6 recipient mice at 300,000 cells per mouse one day
after inoculation with 50,000 B16 cells. **p=0.0021.
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Figure 7.
TRP1 TN cells migrating to the tumor show an exhausted phenotype. A) RAG2−/− mice
were inoculated with 100,000 B16 cells one day prior to transfer of naïve CD8+ T cells from
TRP1high or TRP1low TN mice. Tumor volume was measured over time. **p=0.001.
Representative of 3 independent experiments. B) End stage tumors from mice in A) were
harvested, digested with collagenase and tumor infiltrating lymphocytes were analyzed by
flow cytometry after staining with the indicated antibodies. n=5 mice per group.
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